PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus
As traders log in on Tuesday, November 25, 2025, Plus Therapeutics (NASDAQ:PSTV) is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and a national coverage agreement with Humana for its CNSide® cancer diagnostic. As of the latest completed trading session on Monday, November 24, PSTV last changed hands at $0.5752, up roughly 8% on the day, after trading between $0.50 and $0.59 on volume of about 8.4 million shares. Even after that bounce, the stock still sits well below its 52‑week high
